Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib in Metastatic Pancreatic Cancer
NCT01360853Phase 3Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- May 2011
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of rigosertib in pancreatic adenocarcinoma (PDAC), sponsored by Traws Pharma, Inc.. Started May 2011; status: completed.
02
Drugs
rigosertib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01360853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360853.